Categories: Wire Stories

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

The company is developing next generation lipid-based structures that kill cancer cells and expose cancer to the immune system

HANGZHOU, China–(BUSINESS WIRE)–HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.


“The ASCO meeting is an important opportunity to share our unique lipid-based technology with other clinical investigators,” said Yuhong Xu, Ph.D., Founder and CEO of HighField. “Our lipid-based structures represent a new generation of therapeutics targeting the tumor microenvironment for a broad range of cancers.”

The abstracts reflect Phase 1 clinical trials of two kinds of lipid-based therapeutics. HFK1 is a drug encapsulated immunoliposome containing doxorubicin for patients with advanced refractory solid tumors having HER2 low and HER2+ expression. HER2 expressing solid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA) for patients with recurrent and refractory glioma.

HFK1 Poster Presentation

Abstract ID: 3035

Title: The design, preclinical study and Phase 1 dose escalation of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.

Presenter: Dr. Yuhong Xu, Ph.D.

Presenter Date: Saturday, June 1, 2024 (9am -12pm)

HF1K16 Abstract for Publication

Abstract ID.: e14030

Title: Exploratory phase 1 study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: preliminary efficacy and mechanism as a monotherapy.

About HighField Biopharmaceuticals

HighField is a clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company also has a research and development center and a GMP-compliant production facility. HighField’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. The company’s pipeline also includes drug encapsulated immunoliposomes for solid tumor cancers. For more information visit https://highfield.bio.

Contacts

Media Contact:

Dan Eramian

Opus Biotech Communications

danieleramian@comcast.net
425-306-8716

Business Development Contact:

Donald Wyatt

HighField Biopharmaceuticals

dwyatt@hf-biopharm.com
206-356-8196

Alex

Recent Posts

Singapore – A Trusted Global Supply Chain Management Hub

SINGAPORE - Media OutReach Newswire - 8 November 2024 - Singapore is strengthening its position…

23 mins ago

OPPO Celebrates Global Photography Talent at Paris Photo Fair under the theme of “Dear Life”

PARIS, FRANCE - Media OutReach Newswire – 8 November 2024 - This year, OPPO once…

52 mins ago

ICONSIAM Showcases Thai Culture with “ICONSIAM THAICONIC LOY KRATHONG” Festival, Strengthening Thailand’s Global Standing

This year’s Loy Krathong event at ICONSIAM celebrates Thai cultural heritage, promotes sustainability, and shines…

53 mins ago

KBTG Vietnam and Techsauce Propel Techsauce Global Summit 2024 in Vietnam – Accelerating ASEAN’s Digital Economy

HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 8 November 2024 - KBTG…

2 hours ago

Prince Holding Group’s Chairman Chen Zhi Named Visionary Philanthropist of the Year for Impactful Initiatives in Cambodia

PHNOM PENH, CAMBODIA - Media OutReach Newswire - 8 November 2024 - Neak Oknha Chen…

3 hours ago

Telosin X Debuts in Singapore at The Mineral Boutique: Revolutionizing At-Home Skincare

SINGAPORE - Media OutReach Newswire - 8 November 2024 – Singapore's beauty enthusiasts have a…

4 hours ago